# 1 Title: Ultrasound and biochemical predictors of pregnancy outcome at diagnosis of early-

- 2 onset fetal growth restriction
- 3

# 4 Authors and affiliations:

- 5 Rebecca Spencer<sup>1,2</sup>, Kasia Maksym<sup>1</sup>, Kurt Hecher<sup>3</sup>, Karel Maršál<sup>4</sup>, Francesc Figueras<sup>5</sup>, Gareth
- 6 Ambler<sup>6</sup>, Harry Whitwell<sup>1,7,8</sup>, Nuno Rocha Nené<sup>1</sup>, Neil J. Sebire<sup>9</sup>, Stefan R. Hansson<sup>4</sup>, Anke Diemert<sup>3</sup>,
- 7 Jana Brodszki<sup>4</sup>, Eduard Gratacós<sup>5</sup>, Yuval Ginsberg<sup>1,10</sup>, Tal Weissbach<sup>1,11</sup>, Donald M Peebles<sup>1</sup>, Ian
- 8 Zachary<sup>12</sup>, Neil Marlow<sup>1</sup>, Angela Huertas-Ceballos<sup>13</sup>, Anna L. David<sup>1</sup>
- 9
- 10 <sup>1</sup> UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London,
- 11 UK
- 12 <sup>2</sup> Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
- 13 <sup>3</sup> Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf,
- 14 Hamburg, Germany
- <sup>4</sup> Department of Obstetrics and Gynaecology, Institute of of Clinical Sciences Lund, Skane University
- 16 Hospital, Lund University, Lund, Sweden
- <sup>5</sup> Institut D'Investigacions Biomèdiques August Pi í Sunyer, University of Barcelona, Barcelona Center
- 18 for Maternal-Fetal and Neonatal Medicine, Barcelona, Spain
- <sup>6</sup> Department of Statistical Science, University College London, London, UK
- <sup>7</sup>National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Metabolism,
- 21 Digestion and Reproduction, Imperial College London, London, UK
- <sup>8</sup> Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism,
- 23 Digestion and Reproduction, Imperial College London, London, UK
- <sup>9</sup> Population, Policy & Practice Department, Great Ormond Street Institute of Child Health, University
- 25 College London, London, UK

phote: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

26	<sup>10</sup> Department of Obstetrics and	Gynecology Rambam	Madical Contro	Haifa Israal
20	- Department of Obstetrics and	Gynecology, Rainbain	ineulcal centre	, nalla, islael

- <sup>11</sup> Department of Obstetrics and Gynecology, Sheba Medical Center Tel Hashomer, Tel Aviv, Israel
- 28 <sup>12</sup> Division of Medicine, Faculty of Medical Sciences, University College London, UK
- <sup>13</sup> Neonatal Department, University College London Hospitals NHS Foundation Trust, London, UK

30

#### 31 **Corresponding author:**

- 32 Name: Rebecca Spencer
- 33 Address: LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, LS2 9NL
- 34 Telephone number: 07793 355 359
- 35 Email: r.n.spencer@leeds.ac.uk

36

#### 37 Conflicts of interest:

- 38 RS, KMak, KH, KMar, FF, GA, HW, NRN, NS, SH, AD, EG, YG, TW, IZ and ALD have no conflicts of
- interest to declare; NM declares consultancy fees from InfanDx over the past 12 months.

40

#### 41 Author contributions:

42 RS contributed to study design, patient recruitment, data collection, sample analysis, data analysis

43 and writing the manuscript. KMak contributed to patient recruitment and data collection. KH, KMar,

- 44 FF, SH, AD, JB, EG, DMP, IZ and ALD contributed to study design, patient recruitment and data
- 45 collection. GA contributed to study design and data analysis. HW contributed to sample analysis and
- 46 data analysis. NRN contributed to data analysis. NS contributed to study design and sample analysis.
- 47 YG and TW contributed to patient recruitment and data collection. NM and AHC contributed to
- 48 study design. All authors contributed to critically revising the manuscript, give approval for

49 publication of the work and agree to be accountable for all aspects of it.

50

Page 2

IMPPICT\_JCI\_version\_1

# 51 Abstract

27/01/2023

52

53	Background: Severe early-onset fetal growth restriction (FGR) causes significant fetal and neonatal
54	mortality and morbidity. Predicting the outcome of affected pregnancies at the time of diagnosis is
55	difficult, preventing accurate patient counselling. We investigated the use of maternal serum protein
56	and ultrasound measures at diagnosis to predict fetal or neonatal death and three secondary
57	outcomes: fetal death or delivery $\leq$ 28+0 weeks; development of abnormal umbilical artery Doppler
58	velocimetry; slow fetal growth.
59	Methods: Women with singleton pregnancies (n=142, estimated fetal weights [EFWs] <3rd centile,
60	<600g 20+0-26+6 weeks of gestation, no known chromosomal, genetic or major structural
61	abnormalities), were recruited from four European centres. Maternal serum from the discovery set
62	(n=63) was analysed for seven proteins linked to angiogenesis, 90 additional proteins associated
63	with cardiovascular disease and five proteins identified through pooled liquid chromatography
64	tandem mass spectrometry. Patient and clinician stakeholder priorities were used to select models
65	tested in the validation set (n=60), with final models calculated from combined data.
66	Results: The most discriminative model for fetal or neonatal death included EFW z-score (Hadlock 3
67	formula/Marsal chart), gestational age and umbilical artery Doppler category (AUC 0.91, 95%CI 0.86-
68	0.97) but was less well calibrated than the model containing only EFW z-score (Hadlock3/Marsal).
69	The most discriminative model for fetal death or delivery ≤28+0 weeks included maternal serum
70	placental growth factor (PIGF) concentration and umbilical artery Doppler category (AUC 0.89, 95%CI
71	0.83-0.94).
72	Conclusion: Ultrasound measurements and maternal serum PIGF concentration at diagnosis of
73	severe early-onset FGR predict pregnancy outcomes of importance to patients and clinicians.
74	Trial registration: ClinicalTrials.gov NCT02097667
75	<b>Funding:</b> European Union, Rosetrees Trust, Mitchell Charitable Trust. Page 3

IMPPICT\_JCI\_version\_1

# 76 Introduction

77	The survival and growth of a fetus depends on placental provision of nutrients and waste exchange
78	with the mother. When this system is impaired, by inadequate transformation of the uteroplacental
79	circulation or deficits in the structure or function of the placenta, the fetus fails to reach their
80	growth potential (1, 2). The resulting fetal growth restriction (FGR) may be diagnosed antenatally on
81	the basis of an ultrasound determined low estimated fetal weight (EFW) for gestational age; either
82	<3 <sup>rd</sup> centile or <10 <sup>th</sup> centile with abnormal Doppler ultrasound indices in the uterine (UtA) and/or
83	umbilical (UmA) arteries (3) (4, 5). Early-onset FGR, occurring before 32 weeks of gestation, carries
84	significant risks of stillbirth, neonatal morbidity and mortality, neurodevelopmental impairment, and
85	long-term health problems (6-13). There is currently no treatment that can improve fetal growth in
86	utero; instead, management involves monitoring the pregnancy and timing delivery to balance the
87	risks of stillbirth and prematurity (4, 14-16).
88	
89	An important question when developing novel therapies for early-onset FGR is which pregnancies to
90	include in early-phase clinical trials. There is a balance to be struck between identifying pregnancies
91	that are sufficiently severely affected to justify the possible risks of the intervention but not so
92	severely affected that there is no potential to determine efficacy. Numerous studies have
93	investigated predictive markers for the development of FGR (17-22), but far fewer have studied the
94	prediction of pregnancy outcome when early-onset FGR is diagnosed. Lack of knowledge about
95	pregnancy outcome in FGR makes it difficult to optimise the inclusion criteria for clinical trials, but it
96	also leaves pregnant patients and their partners with a considerable burden of uncertainty (23, 24).
97	
98	The EVERREST Project aims to carry out a phase I/IIa trial of maternal vascular endothelial growth
99	factor (VEGF) gene therapy for early-onset FGR (25). The greatest potential for benefit is in
100	pregnancies at the threshold of viability, for whom our current management option, preterm

Page 4

**IMPPICT JCI version 1** 

101 delivery, is not possible or is very high risk. In preparation for a clinical trial of a novel therapeutic, 102 we established a multicentre prospective study to characterise the natural history of early-onset 103 FGR, choosing an extreme phenotype in which the estimated fetal weight (EFW) was <3<sup>rd</sup> centile and <600g between 20+0 and 26+6 weeks of gestation (henceforth referred to as 'severe' early-onset 104 105 FGR) (26). 106 107 The aim of this work was to prospectively identify and validate ultrasound and serum biochemical 108 factors that could be used to predict fetal or neonatal death in pregnancies affected by severe early-109 onset FGR. These could subsequently be used to select the most appropriate women for a first-in-

110 human study of a novel therapeutic to treat FGR, and to better counsel women and their partners

about pregnancy outcome. To this end, we asked patients and clinicians to assess the value of our

112 primary and secondary outcomes, based on which we then selected models for validation.

113 Unsupervised parenclitic network analysis by pregnancy outcome and functional network analysis of

114 proteins associated with pregnancy outcomes were also performed to maximise the utility of the

proteomic data with the aim of providing insights into the underlying pathophysiology.

# 116 **Results**

117 The discovery set, recruited between March 2014 and September 2016, comprised 63 pregnant participants (Figure 1 & Table 1; supplementary data Table 1). Follow-up for the ascertainment of 118 119 study outcomes was completed in November 2016. The validation set, recruited between October 120 2016 and January 2020, comprised 60 pregnant participants, with follow-up for the ascertainment of 121 study outcomes completed in March 2020. There were no significant differences in maternal 122 demographics, pregnancies characteristics or pregnancy outcomes between the discovery and 123 validation sets (Table 1; supplementary data Table 2 & Figure 1). Overall, 42 (34%) of the 124 pregnancies ended in the primary outcome of fetal or neonatal death (within the first 28 days of 125 life). For the three secondary outcomes, only fetal death or delivery  $\leq 28+0$  weeks of gestation could Page 5

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

- 126 be ascertained for all pregnancies, occurring in 58 cases (47%). The UmA Doppler velocimetry was
- normal (<95<sup>th</sup> centile for gestation (27)) at enrolment in 46 participants, of whom 21 (46%)
- 128 subsequently developed abnormal UmA Doppler measurements. Fetal growth trajectory (based on
- 129 change in percentage weight deviation over a period or two weeks or more (28)) could be assessed
- 130 for 104 pregnancies (85%), with the remaining pregnancies ending in fetal death or delivery before a
- 131 2-week interval was reached. Forty-one of these 104 fetuses (39%) demonstrated slow fetal growth
- 132 (worsening of weight deviation of  $\geq$ 10 percentage points). A smaller proportion of fetuses
- demonstrated slow fetal growth in the validation set (31%) than in the discovery set (47%).

#### 134



135

- 136 Figure 1: Flow diagram of participant eligibility and enrolment across the four EVERREST Prospective
- 137 Study centres from 10th March 2014 to 30th January 2020 for the discovery and validation sets.

138

139

Page 6

#### IMPPICT\_JCI\_version\_1

- Table 1: Characteristics and outcomes of the discovery, validation and combined participant sets. 140
- 141 Discovery and validation sets were compared using 2-sided t tests for symmetrical continuous
- 142 variables, Mann-Whitney U tests for skewed continuous variables and chi square or Fisher's exact
- tests (where specified) for categorical variables. 143

	Discovery	Validation	p value	Combined
	n=63	n=60		n=123
	Maternal charad	cteristics		<u>.</u>
Maternal age, mean years (SD)	33.7 (6.0)	33.3 (6.7)	0.72	33.5 (6.3)
Primiparous, n (%)	43 (68)	37 (62)	0.44	80 (65)
BMI, median (IQR)	24.9 (22.7-28.6)	26.4 (22.8-31.0)	0.36	25.7 (22.8-30.0)
Ethnicity, n (%) <sup>1</sup>				
White	42 (67)	27 (46)	0.16	69 (57)
Black	10 (16)	15 (25)		25 (20)
Asian	10 (16)	15 (25)		25 (20)
Other	1 (2)	2 (3)		3 (2)
Essential hypertension, n (%)	10 (16)	6 (10)	0.33	16 (13)
Pre-eclampsia at enrolment, n (%)#	4 (6)	5 (8)	0.47	9 (7)
E	nrolment ultrasound	measurements		
Gestational age at enrolment.	23+6	23+5	0.48	23+5
median weeks+days (IQR) [range]	(22+3-25+1)	(22+3-24+4)		(22+3-24+5)
	[20+1-26+5]	[20+4-26+4]		[20+1-26+5]
EFW at enrolment, median grams	392 (281-503)	387 (280-448)	0.61	389 (281-484)
(IQR) (29)				
EFW z-score at enrolment, median	-3.0	-3.2	0.17	-3.1
(IQR) (29, 30)	(-3.6 to -2.5)	(-3.8 to -2.7)		(-3.7 to -2.6)
Mean UtA PI >95 <sup>th</sup> centile at	49 (79)	49 (82)	0.71	98 (80)
enrolment, n (%)² (27)				
UmA PI >95 <sup>th</sup> centile at enrolment,	32 (51)	36 (60)	0.26	78 (55)
n (%) <sup>3</sup> (27)				
Absent or reversed UmA end-	18 (29)	25 (42)	0.11	43 (35)
diastolic flow at enrolment, n (%) <sup>3</sup>				
MCA PI <5 <sup>th</sup> centile at enrolment, n	10 (16)	7 (12)	0.41	17 (15)
(%) <sup>4</sup> (27)	- (-)	- (-)		- (-)
DV a wave absent or reversed at	5 (8)	4 (7)	0.51	9 (8)
enrolment, n (%) <sup>5#</sup>				
	Pregnancy out	tcomes	1	
Pre-eclampsia at any point in	24 (39)	17 (33)	0.51	41 (36)
pregnancy, n (%) <sup>6</sup>				
Gestational age at diagnosis of	28+2	28+2	0.90	28+2
stillbirth or delivery of live birth,	(26+3-34+0)	(26+4-33+2)		(26+3-33+2)
median weeks+days (IQR) [range]	[21+4-39+3]	[22+2-39+6]		[22+2-39+6]
Female fetus / infant, n (%) <sup>7</sup>	36 (57)	24 (43)	0.19	60 (50)
Caesarean delivery, n (%)	42 (67)	37 (63)	0.65	79 (65)
Live births, n (%)	47 (75)	43 (72)	0.71	90 (73)
	n=47	n=43		n=90
Live births ≤28+0 weeks, n (%)	15 (32)	14 (33)	0.95	29 (32)
Live births >37 weeks, n (%)	8 (17)	10 (23)	0.46	18 (20)
Caesarean delivery for live births, n	42 (89)	37 (88)	0.85	79 (89)
(%)	- />			
Neonatal deaths, n (%) <sup>#</sup>	5 (11)	4 (9)	0.56	9 (10)

Page 7

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

Birth weight z-score for live births, mean (SD) (30)	-3.5 (1.1)	-3.5 (0.9)	0.97	-3.5 (1.0)
	Study outco	mes		
	n=63	n=60		n=123
Fetal or neonatal death, n (%)	21 (33)	21 (35)	0.85	42 (34)
Death or delivery ≤28+0 weeks of	30 (48)	28 (47)	0.92	58 (47)
gestation, n (%)				
	n=55	n=49		n=104
Slow fetal growth, n (%)	26 (47)	15 (31)	0.083	41 (39)
	n=26	n=20		n=46
Development of UmA PI >95 <sup>th</sup>	12 (46)	9 (45)	0.94	21 (46)
centile, n (%)				

<sup>1</sup>n=1 missing from validation, <sup>2</sup>n=1 missing from discovery, <sup>3</sup>n=1 missing from validation, <sup>4</sup>n=5

145 missing from discovery and n=1 missing from validation, <sup>5</sup>n=3 missing from discovery and n=1

146 missing from validation, <sup>6</sup>n=1 missing from discovery and n=8 missing from validation, <sup>7</sup>n=5 missing

147 from validation, #Fisher's exact test. DV=ductus venosus, EFW=estimated fetal weight, MCA=middle

148 cerebral artery, PI=pulsatility index, UmA=umbilical artery, UtA=uterine artery.

149

#### 150 Ultrasound measurements as predictors of fetal or neonatal death and death or delivery ≤28+0

151 weeks of gestation in the discovery set: The best ultrasound predictor of fetal or neonatal death

152 was EFW z-score, either as calculated using the Hadlock 3 formula and Marsal chart (EFW<sub>HM</sub>: AUC

153 0.81, 95% CI 0.69-0.93) or the Intergrowth formula and chart (EFW<sub>Int</sub>: AUC 0.83, 95% CI 0.71-0.95).

154 UmA category (<95th centile; >95th centile with positive EDF; absent EDF; reversed EDF. AUC 0.75,

155 95% CI 0.62-0.88) and slow fetal growth (AUC 0.70, 95% CI 0.56-0.83) were also fair predictors. UmA

156 category was the best predictor of death or delivery ≤28+0 weeks (AUC 0.80, 95% CI 0.70-0.91), with

157 mean UtA PI (AUC 0.77, 95% CI 0.65-0.89) and Intergrowth EFW z-score (AUC 0.73, 95% CI 0.60-0.85)

also fair predictors (supplementary data Tables 3 & 4).

159 **Proteomics:** Mass spectrometry (MS) profiling of pooled samples gave quantitative information for

160 200 protein groups (sets of proteins that cannot be distinguished based on peptide sequences), from

161 which human placental lactogen (HPL), fibronectin, pregnancy-specific beta-1 glycoprotein (PSG1),

serum amyloid A (SAA) and leucyl-cystinyl aminopeptidase (LNPEP) were selected for individual

163 validation, based on the scoring system outlined in the methods.

Page 8

**IMPPICT JCI version 1** 

#### 164 Univariate associations between maternal serum protein concentrations and outcomes in the

- 165 discovery set: Four proteins were undetectable in most of the samples: VEGF-A, natriuretic peptides
- 166 B (BNP), melusin, poly[ADP-ribose] polymerase 1 (PARP1). These were excluded from further
- 167 prediction analyses. The associations between the remaining 98 proteins and the four pregnancy
- 168 outcomes are summarised in Figure 2. Placental growth factor (PIGF) and HPL concentration were
- significantly associated with fetal or neonatal death (after Benjamini-Hochberg correction), with 169
- 170 fold-changes of 0.52 in pregnancies ending in fetal or neonatal death compared with pregnancies
- 171 ending in neonatal survival. The concentrations of nine proteins were significantly associated with
- death or delivery ≤28+0 weeks (after correction). The greatest magnitudes of fold-changes were 172
- seen for PIGF (0.28), HPL (0.45), and PSG1 (0.48). 173
- 174

Page 9

**IMPPICT JCI version 1** 



177

Figure 2: Volcano plots showing the statistical significance and magnitude of the associations
between the 98 proteins and four pregnancy outcomes in the discovery set. Associations tested with
2-sided t tests for symmetrical data and Mann-Whitney U tests for skewed data. Dotted line
indicates a p value of 0.05. Dashed line indicates the Benjamini-Hochberg cut-off with a 5% false
discovery rate (p=0.0015 for fetal or neonatal death, p=0.005 for death or delivery ≤28+0 weeks).
See supplementary data Table 5 for full protein names.

184

185

**IMPPICT JCI version 1** 

	.86 F	Parenclitic network anal	ysis of the discovery set:	: Both the networks	s for fetal or	neonatal death	and
--	-------	--------------------------	----------------------------	---------------------	----------------	----------------	-----

- 187 death or delivery  $\leq$  28+0 weeks contained clusters centred around HPL (clusters 6 and 4, Figure 3).
- These clusters also contained pentraxin-related protein PTX3, spondin-2 (SPON2) and 188
- 189 thrombomodulin (TM) and contained or were linked to decorin (DCN). The network for death or
- 190 delivery  $\leq 28+0$  weeks also contained a cluster centred around PIGF (cluster 2). For all three of the
- 191 networks that included fetal sex, similar clusters emerged that contained renin (REN), angiopoietin 1
- 192 (ANG1), dickkopf-related protein 1 (DKK1) and platelet-derived growth factor subunit beta (PDGFB),
- 193 contained or were linked to pregnancy-associated plasma protein A (PAPP-A) and in two of the three
- 194 networks included lectin-like oxidized LDL receptor 1 (LOX1). Networks and associated dendrograms
- for the development of abnormal umbilical artery Dopplers and slow fetal growth are provided in 195
- supplementary data Figures 4 & 5. 196

197

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1



198

199

200 Figure 3: Parenclitic networks for clusters generated based on: (A) fetal or neonatal death (B) death

201 or delivery ≤28+0 weeks. See supplementary data Table 5 for full protein names and supplementary

202 data Figures 2 & 3 for associated dendrograms.

203

Page 12

perpetuity. All rights reserved. No reuse allowed without permission.

**IMPPICT JCI version 1** 

204 **Model selection by stakeholders:** None of the single variable or multivariable models for predicting 205 slow fetal growth performed well enough to warrant validation (AUCs <0.70). For the three 206 remaining outcomes, an online survey was performed to ascertain the priorities of clinicians and patients in predicting outcomes. Forty-five clinicians from 18 countries (of 173 contacted, 26%) and 207 208 seven patients from the UK who had experienced a pregnancy complicated by severe early-onset 209 FGR (of 36 contacted, 19%) responded (supplementary data Table 6). The prediction of fetal or 210 neonatal death and death or delivery  $\leq$ 28+0 weeks were considered important or very important by 211 all patients and were also rated highly by clinicians for the purposes of patient counselling and 212 clinical management (Figure 4). Patients and clinicians marginally prioritised sensitivity over 213 specificity for most outcomes (supplementary data Figure 6). For the prediction of the development of abnormal UmA PI, patients universally prioritised sensitivity while clinicians marginally prioritised 214 215 specificity for patient counselling.



Кеу	Very important Important
Patient priorities	
Clinical management	
Patient counselling	

229

230 Figure 4: The proportion of patients who ranked our three pregnancy outcomes as 'important' or

231 'very important' and the proportion of clinicians who ranked them as 'important' or 'very important'

for clinical management and for patient counselling. UmA PI=umbilical artery pulsatility index.

233

Page 13

#### All rights reserved. No reuse allowed without permission.

#### IMPPICT\_JCI\_version\_1

234 Based on the survey results, the model performance metrics and the assay reliability, models 235 containing the variables listed in Tables 2 and 3 were selected for validation. For the prediction of 236 death or delivery <28+0 weeks, models including HPL marginally outperformed models including 237 PIGF. However, possibly related to the short processing time, the commercial HPL ELISA had high 238 intra-assay variability in our hands (mean coefficient of variation 8.0%, SD 7.3%, 28% requiring 239 repeat analysis for coefficient of variation >10%). Because of this, and the existence of clinically 240 approved tests for PIGF, models including PIGF were selected for validation. 241 Model validation: Five of the seven protein models (Table 2) and all five of the models containing 242 ultrasound measurements (Table 3), generated in the discovery set, were successfully validated, 243 with AUCs included in the AUC 95% CIs generated from the discovery cross-validation estimates. 244 Addition of pregnancy characteristics: Validated models were not significantly improved by the 245 addition of maternal BMI, maternal age, maternal ethnicity or fetal sex. Adding gestational age at 246 enrolment significantly improved the models containing EFW<sub>HM</sub> alone (LR test p=0.0001) and EFW<sub>HM</sub> 247 with UmA category (LR test p<0.00005) to predict fetal or neonatal death (supplementary data Table 248 7). The addition of 'pre-eclampsia at enrolment' significantly improved all validated models 249 predicting fetal death or delivery  $\leq 28$  weeks of gestation (supplementary data Table 7). 250 PIGF values for maximum likelihood ratios: Receiver operating characteristic (ROC) curves are 251 shown in Figures 5 and 6. Model constants and coefficients, along with optimal cut points for 252 positive and negative likelihood ratios and correct classification are provided in supplementary data 253 Tables 8 and 9. Serum PIGF concentration <14.2 pg/ml predicted fetal or neonatal death with a 254 positive likelihood ratio of 18.3, sensitivity of 45% and specificity of 98% and correctly classified 80% 255 of participants. Serum PIGF concentration <14.5 pg/ml predicted death or delivery ≤28+0 weeks with 256 a positive likelihood ratio of 24.7, sensitivity of 38% and specificity of 98% and correctly classified 257 70% of participants.

258

Page 14

**IMPPICT JCI version 1** 

- 259 Table 2: Model validation for predicting adverse pregnancy outcomes: the seven pre-specified
- models containing maternal serum proteins. The model not validated is shaded. Validated models 260
- include estimates from the combined discovery and validation sets. 261

Outcomes	Variable(s)	Discovery		Validation		Combined	
		(witl	n LOOCV)				
		AUC	95% CI	AUC	95% CI	AUC	95% CI
Fetal or	PIGF	0.75	0.62-0.88	0.83	0.72-0.95	0.81	0.73-0.89
neonatal	PIGF & lymphotactin	0.84	0.73-0.95	0.75	0.62-0.88	0.83	0.75-0.91
death	PIGF, lymphotactin & fibronectin	0.85	0.74-0.96	0.69	0.55-0.83		
	PIGF	0.86	0.76-0.96	0.76	0.64-0.88	0.82	0.75-0.89
Death or delivery ≤28+0	PIGF & pre- eclampsia					0.84	0.77-0.91
, weeks	PIGF & PSG1*	0.91	0.82-0.99	0.80	0.69-0.91	0.86	0.80-0.93
	PIGF, PSG1 & pre- eclampsia					0.88	0.82-0.94
Development	PIGF	0.84	0.50-0.95	0.64	0.38-0.89	0.78	0.64-0.91
of abnormal	PIGF & fibronectin	0.88	0.74-1.00	0.65	0.39-0.90	0.80	0.67-0.93
UmA PI							

\*Discovery AUC 0.906, validation 95% CI 0.688-0.912. LOOCV=leave-one-out cross-validation, 262

263 PI=pulsatility index, PIGF=placental growth factor, PSG1=pregnancy-specific beta-1 glycoprotein,

UmA=umbilical artery. Models were generated and tested using the natural log of PIGF in pg/ml and 264

265 centered and scaled values for lymphotactin normalised protein expression (NPX) on a log2 scale.

266

267

Page 15

perpetuity. All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

- 268 Table 3: Model validation for predicting adverse pregnancy outcomes: models containing ultrasound
- 269 measurements, maternal serum protein concentrations and pregnancy characteristics, and their
- 270 final AUCs from the combined discovery and validation sets.

Outcomes	Variable(s)	Discovery		Validation		Combined	
		(witl	h LOOCV)				
		AUC	95% CI	AUC	95% CI	AUC	95% CI
Fetal or	EFW <sub>HM</sub> z-score	0.78	0.66-0.91	0.89	0.80-0.97	0.85	0.78-0.92
neonatal	EFW <sub>HM</sub> z-score & GA					0.90	0.84-0.96
death	EFW <sub>Int</sub> z-score	0.80	0.67-0.93	0.91	0.83-0.99	0.87	0.80-0.94
	EFW <sub>HM</sub> z-score & UmA	0.78	0.64-0.91	0.88	0.80-0.97	0.86	0.79-0.93
	category <sup>1</sup>						
	EFW <sub>HM</sub> z-score, UmA					0.91	0.86-0.97
	category & GA <sup>1</sup>						
	UmA category <sup>1</sup>	0.78	0.67-0.89	0.79	0.68-0.91	0.80	0.72-0.88
Death or	UmA category & pre-					0.84	0.77-0.91
delivery	eclampsia <sup>1</sup>						
≤28+0	UmA category & PIGF <sup>1</sup>	0.89	0.81-0.97	0.85	0.75-0.94	0.89	0.83-0.94
weeks	UmA category, PIGF &					0.90	0.85-0.95
	pre-eclampsia <sup>1</sup>						

271 <sup>1</sup>n=1 missing from validation set. EFW<sub>HM</sub>=estimated fetal weight calculated using Hadlock 3 formula

272 (29) with z-score calculated using Marsal reference chart (30), EFW<sub>Int</sub>=estimated fetal weight and z-

273 score calculated using Intergrowth formulae (31), GA=gestational age at enrolment in days,

274 LOOCV=leave-one-out cross-validation, PIGF=placental growth factor, UmA=umbilical artery.

275

Page 16

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1



### 276

Figure 5: Comparison of the receiver operating characteristic (ROC) curves for the models predicting
fetal or neonatal death. EFW-HM=estimated fetal weight calculated using Hadlock 3 formula (29)
with z-score calculated using Marsal reference chart (30), EFW-Intergrowth=estimated fetal weight
and z-score calculated using Intergrowth formula and reference chart (31), GA=gestational age at
enrolment, PIGF=placental growth factor concentration, UmA=umbilical artery Doppler category
(0=pulsatility index <95th centile, 1=pulsatility index >95th centile, 2=absent end-diastolic flow,

283 3=reversed end-diastolic flow).



#### 284



Page 17

IMPPICT\_JCI\_version\_1

291	Alternative EFW formulae: Although the EFW z-score calculated using the Intergrowth formula and
292	chart gave the highest AUC for predicting fetal or neonatal death, the Intergrowth formula for
293	estimating fetal weight performed poorly in our sample, especially at lower fetal weights. For the 21
294	livebirths with a birthweight <600g and an EFW performed within seven days of delivery, the
295	Intergrowth formula overestimated birthweight by a mean of 47% (SD 14%), in contrast to the
296	Hadlock 3 formula which overestimated birthweight by a mean of 25% (SD 10%, supplementary data
297	Figure 8). For all 67 livebirths with an EFW performed within seven days of delivery, the Intergrowth
298	formula overestimated birthweight by a mean of 29% (SD 20%) and the Hadlock 3 formula
299	overestimated birthweight by a mean of 15% (SD 13%). As might be expected, using the EFW
300	calculated from one formula in the model derived from the other had a substantial negative impact
301	on calibration (supplementary data Figure 9).
302	Re-analysis of the combined sets: Combining the centred and scaled data from the discovery and
303	validation sets, the strongest associations with both fetal or neonatal death, and death or delivery
304	$\leq$ 28+0 weeks were the previously observed negative associations with PIGF (p=1.4x10 <sup>-8</sup> and
305	$p=3.0x10^{-11}$ ) and HPL ( $p=1.3x10^{-7}$ and $p=1.4x10^{-10}$ ) (Figure 7). The evidence for the negative
306	association between PSG1 and both outcomes was strengthened, as was the evidence for negative
307	associations between matrix metalloproteinase-12 (MMP12) and programmed cell death 1 ligand 2
308	(PDL2) and death or delivery $\leq$ 28+0 weeks. None of the proteins showed an association with the
309	development of abnormal UmA Dopplers or slow fetal growth at a Benjamini-Hochberg 5% false
310	discovery rate (supplementary data Figure 10).
311	

Page 18

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1





Figure 7: Volcano plots showing the statistical significance and magnitude of associations between
fetal and neonatal death and death or delivery ≤28+0 weeks and the centred and scaled
concentrations of the 93 proteins from the discovery and validation sets combined. Associations
tested with 2-sided t tests. Dotted line indicates p=0.05, short-dashed line indicates BenjaminiHochberg cut-off with a 5% false discovery rate (A p=0.0048, B p=0.012), long-dashed line indicates
Benjamini-Hochberg cut-off with a 1% false discovery rate (A p=0.00032, B p=0.0013). See
supplementary data Table 10 for full protein names and individual -log10 p values.

320

Functional analysis of the proteins associated with fetal or neonatal death at a 5% false discovery
 rate demonstrated co-expression of HPL and GH. Expanding the network to include intervening
 proteins resulted in clusters sharing GO biological processes of growth hormone receptor signalling,
 VEGF signalling and calcitonin family receptor signalling, with proteins in the latter two clusters also
 involved in angiogenesis and regulation of angiogenesis (Figure 8). Proteins associated with death or
 Page 19

IMPPICT\_JCI\_version\_1

delivery ≤28+0 weeks showed multiple interactions, predominantly centred on fibronectin. Shared

327 GO biological processes included those relating to growth (regulation of angiogenesis, cellular

328 response to growth factors and growth hormone receptor signalling pathway via jak-stat), immune

- 329 function (leucocyte migration, inflammatory response, and positive regulation of T cell activation) or
- both (regulation of cell adhesion, positive regulation of nik/NF-kappaB signalling) (Figure 9).

331



332

**333** Figure 8: An expanded functional network demonstrating interactions and shared GO biological

334 processes of the proteins associated with fetal or neonatal death in the combined data set at a

335 Benjamini-Hochberg false discovery rate of 5%. Red=growth hormone receptor signalling pathway,

336 yellow=vascular endothelial growth factor signalling pathway, green=calcitonin family receptor

337 signalling pathway, light blue=regulation of angiogenesis, dark blue=angiogenesis. See

338 supplementary data Table 5 for full protein names. Analysis, graphic and legend from STRING (Swiss

339 Institute of Bioinformatics)(32).

340

Page 20

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1



342 Figure 9: Functional interactions and shared GO biological processes of the proteins associated with death or delivery  $\leq$  28+0 weeks in the combined data set at a Benjamini-Hochberg false discovery 343 344 rate of 5%. Red=growth hormone receptor signalling pathway via jak-stat, orange=inflammatory 345 response, yellow=leukocyte migration, light green=extracellular matrix, dark green=regulation of cell 346 adhesion, light blue=regulation of angiogenesis, dark blue=cellular response to growth factor 347 stimulus, pink=positive regulation of nik/NF-kappaB signalling, purple=positive regulation of T cell activation. See supplementary data Table 5 for full protein names. Analysis, graphic and legend from 348 STRING (Swiss Institute of Bioinformatics)(32). 349

350

341

351 The three best performing LOOCV models using the combined centred and scaled data all included

352 pro-adrenomedullin (ADM) for predicting fetal or neonatal death, PIGF and HPL for predicting death

353 or delivery ≤28+0 weeks and Platelet-derived growth factor subunit B (PDGFB) for predicting the

- development of abnormal UmA Doppler measurements (supplementary data Table 12). The
- 355 emergence of ADM in the models predicting fetal or neonatal death was consistent with the
- 356 significant association present in the combined but not the discovery sets. In contrast, PDGFB didPage 21

**IMPPICT JCI version 1** 

not show significant univariate associations with the development of abnormal UmA Dopplers in the
discovery, validation, or combined data sets.

359 Predicting gestational age of livebirth or diagnosis of fetal death and interval from enrolment to 360 livebirth or diagnosis of fetal death: Twelve protein and ultrasound measurements showed an 361 association with the gestational age at which the pregnancies ended in livebirth or fetal death, at a 362 1% Benjamini-Hochberg false discovery rate (supplementary data Table 13). The best model to predict gestational age at livebirth or fetal death included PIGF and sflt1 concentrations, MMP12 and 363 364 IL1RL2 NPX and UmA category at enrolment (Figure 10). Eight protein and ultrasound measurements 365 showed an association with the interval between enrolment and either livebirth or the diagnosis of 366 fetal death at a 1% Benjamini-Hochberg false discovery rate (supplementary data Table 13). The best 367 model to predict the interval between enrolment and livebirth or fetal death included PIGF and sflt1 368 concentrations, MMP12 and decorin NPX, UmA category and gestational age at enrolment (Figure 369 10). Both models accounted for 68% of the variation in the outcomes they were predicting but had 370 95% prediction intervals of 40 days, limiting their clinical utility. Sparser models, including PIGF and 371 sflt1 concentrations and UmA category to predict gestational age at livebirth or fetal death, and 372 these same variables plus gestational age at enrolment to predict interval to livebirth or fetal death, 373 had only slightly wider 95% prediction intervals of 42 days (supplementary data Figure 11).

374

All rights reserved. No reuse allowed without permission.

**IMPPICT JCI version 1** 



376 Figure 10: (A) Predicted versus actual gestational age of either livebirth or diagnosis of fetal death, 377 based on the model containing PIGF and sflt1 concentrations, decorin and matrix metalloproteinase 378 12 normalised protein expression and umbilical artery Doppler category. (B) Predicted versus actual 379 interval from enrolment to either livebirth or diagnosis of fetal death, based on the model 380 containing PIGF and sflt1 concentrations, decorin and matrix metalloproteinase 12 normalised 381 protein expression, umbilical artery Doppler category and gestational age at enrolment. Green filled 382 circles=pregnancies ending in livebirth, red hollow circles=pregnancies ending in fetal death, dotted 383 lines=95% prediction intervals.

384

375

Placental histological classification: Placental samples for histological examination were available 385 386 for 55 pregnancies (45%); these had similar characteristics and outcomes to the pregnancies without 387 available samples (supplementary data Tables 14 & 15). The only statistically significant difference 388 was a higher proportion of female fetuses among the pregnancies that had placental samples than 389 those that did not (63% vs 41%, p=0.016). Forty-five (82%) placentas showed evidence of placental 390 pathology, with 39 (71%) classified as maternal vascular malperfusion (MVM), three (5%) as villitis of 391 unknown aetiology (VUE), one (2%) as fetal vascular malperfusion (FVM) and two (4%) as non-392 specific dysmorphic villi. Twelve of the 14 placental samples from pregnancies ending in stillbirth 393 showed MVM, while the three available samples from pregnancies ending in neonatal death showed

Page 23

**IMPPICT JCI version 1** 

VUE, FVM and dysmorphic villi. Mean UtA PI, maternal serum PIGF and maternal serum PAPP-A at
enrolment all differed significantly between pregnancies with subsequent MVM and pregnancies
without MVM. In contrast, none of the umbilical artery parameters studied (UmA category at
enrolment; the occurrence of UmA PI >95<sup>th</sup> centile at any point before delivery; the occurrence of
absent or reversed UmA end-diastolic flow at any point before delivery) showed evidence of an
association with placental histological classification of MVM (supplementary data Table 16).

## 400 **Discussion**

#### 401 Principle findings and significance

402 To our knowledge this is the first study to use a discovery science approach, combining ultrasound

403 and biochemical parameters, to identify and validate prognostic markers at the time of diagnosis of

404 severe early-onset FGR. These findings can be used to inform personalised counselling and

405 management of affected pregnancies with outcomes of importance to patients and clinicians.

406 Furthermore, by providing alternative thresholds that prioritise positive and negative likelihood

407 ratios and maximum correct categorisation, eligibility criteria for clinical trials of novel therapeutics

408 can be adapted depending on the perceived risk: benefit ratio of the intervention.

409 Our secondary analyses, including parenclitic network analysis, functional enrichment analysis and

410 triangulation with placental histological classification, provide a deeper characterisation of this

411 unique case series. Some of these findings support and enhance our existing understanding of

412 placental FGR, such as the interplay between angiogenesis, immune cells, and the extracellular

413 matrix (33-35). Other findings offer new avenues for investigation, such as the parenclitic network

414 cluster around fetal sex, which includes proteins related to pericyte function (36).

415

#### 416 Findings in the context of existing literature

417 Given that ultrasound assessment of biometry and Doppler velocimetry forms the mainstay of

418 identifying and monitoring FGR, it is unsurprising that EFW z-score and umbilical artery category Page 24

IMPPICT\_JCI\_version\_1

419	were validated as predictors of fetal or neonatal death and fetal death or delivery ≤28+0 weeks
420	respectively (37-39). A secondary analysis of 105 pregnancies from the UK placebo-controlled trial of
421	sildenafil citrate for early-onset FGR (STRIDER; EFW or AC <10 <sup>th</sup> centile with absent or reversed UmA
422	end-diastolic flow at 22+0-29+6 weeks) identified EFW as an independent predictor of livebirth (OR
423	per 100g 4.3, 95%Cl 2.3-8.0, p<0.001) and overall survival (OR per 100g 2.9, 95%Cl 1.8-4.4,
424	p<0.001)(40). What is less expected is that absent or reversed ductus venosus a wave was a poor
425	predictor of fetal or neonatal death in our participants (AUC 0.59, 95% CI 0.53-0.66, see
426	supplementary material Table 4), in contrast to the results of previous studies (41, 42). This may
427	reflect a change in clinical practice since these studies were published. Their findings led to ductus
428	venosus waveform becoming an important factor in timing of delivery in extremely pre-term FGR
429	(14, 43), which may have altered the natural history of the disease by prompting delivery before
430	stillbirth could occur.
431	A limitation of using ultrasound parameters is their potential for variation. In the case of Doppler
432	velocimetry this includes interobserver variability, temporal variation due to factors such as
433	maternal and fetal movement, and variation in umbilical artery waveforms between arteries and
434	along the length of the cord (44-47). There is also considerable variation between different Doppler
435	reference ranges, both in terms of the values of their 'normal' ranges and their methodological
436	quality(48). In the case of EFW z-score, variation arises from interobserver variability in measuring
437	biometry, variation in formulae used to generate the EFW and variation in charts used to determine
438	the z-score for gestational age (49-51). Despite the methodological limitations of the Hadlock 3
439	formula, a recent study of 65 pregnancies with early-onset FGR delivered within seven days of
440	ultrasound assessment found it gave a better combination of systematic and random error than 20
441	other formulae tested (52).
442	Several recent studies have highlighted the potential utility of PIGF concentration to predict

443 outcomes in SGA and FGR pregnancies. In a case series of 173 singleton pregnancies with a

Page 25

## IMPPICT\_JCI\_version\_1

444	customised EFW <10 <sup>th</sup> centile between 20+0 and 31+6 weeks, the sflt1/PIGF ratio at diagnosis was
445	an excellent predictor of delivery <30 weeks (AUC 0.96, 95% CI 0.93->0.99) and <34 weeks (AUC
446	0.94, 95% CI 0.89-0.98) and a good predictor of a composite adverse perinatal outcome (AUC 0.83,
447	95% CI 0.77-0.90) (53). Similarly, in 116 singleton pregnancies with early-onset FGR (customised EFW
448	$< 3^{rd}$ centile or customised EFW $< 10^{th}$ centile with abnormal UmA and/or UtA Doppler velocimetry;
449	<32+0 weeks) and positive UmA end-diastolic flow ending in livebirth, women with an sflt1/PIGF
450	ratio ≥85 were significantly more likely to deliver within one, two, three and four weeks from ratio
451	measurement than women with an sflt1/PIGF ratio <85 (54). Composite neonatal morbidity and
452	neonatal admission were also significantly higher following pregnancies with a sflt1/PIGF ratio ≥85
453	(53.8% vs 28.6% p=0.04; 97.5% vs 67.9% p<0.01). More strikingly, in a series of 130 singleton
454	pregnancies with SGA (AC or EFW <10 <sup>th</sup> centile), fetal demise only occurred in pregnancies with a
455	PIGF <10 <sup>th</sup> centile for gestational age at any time between 16 and 36 weeks (12/65 vs 0/65,
456	p<0.0001) (55).
457	While these studies revealed the PIGF results to the managing clinicians, similar results have been
458	found in studies where PIGF was not revealed. The secondary analysis of STRIDER UK trial
459	participants, mentioned above, found significant associations between pregnancy outcomes and
460	both the sflt1/PIGF ratio and PIGF alone (40). Higher PIGF concentrations and a lower sflt1/PIGF
461	ratios were associated with greater overall survival (PIGF coefficient 3.67, p<0.001; ratio coefficient
462	0.51, p=0.002) and later gestation at birth (PIGF coefficient 1.4, p<0.001; ratio coefficient -0.99,
463	p<0.001). Similarly, in a multinational case series of 411 pregnancies, PIGF <5 <sup>th</sup> centile at the time of
464	suspected FGR (AC <10 <sup>th</sup> centile from 20+0 weeks) had an 87.5% sensitivity and 62.8% specificity for
465	predicting stillbirth (56). PIGF <12 pg/ml was associated with a shorter interval to delivery than PIGF
466	>5 <sup>th</sup> centile (13.0 vs 29.5 days, p<0.0001).

Our finding that placental histological classification of maternal vascular malperfusion was 467

468 significantly associated with lower maternal PIGF concentration and higher mean uterine artery PI at

Page 26

#### All rights reserved. No reuse allowed without permission.

## IMPPICT\_JCI\_version\_1

469 diagnosis of early-onset FGR, but not with UmA Doppler measurements, was in keeping with the 470 results of previous studies (56-59). Agrawal et al. have recently reported that MVM, unlike other placental pathologies, is characterised by raised mean uterine artery PI and a gradual decline in PIGF 471 472 as the pregnancy progresses (57). Triunfo et al. found in SGA pregnancies (EFW <10<sup>th</sup>) identified 473 between 30 and 34 weeks of gestation, a pattern of placental histopathology they termed 'placental 474 underperfusion', was most strongly associated with lower PIGF, measured at the time of diagnosis 475 (58). Benton et al. also found low PIGF to be a better predictor of placental pathology than umbilical 476 artery resistance index or abdominal circumference centile (56).

477

#### 478 Strengths and limitations

479 The strengths of this multicentre study are that it was carried out prospectively in academic health 480 science centres with fetal medicine experts trained on a common ultrasound protocol, and level 3 481 perinatal care available for delivery. Participants and their fetuses/neonates were extensively 482 phenotyped at study entry, for the duration of the pregnancy and postnatally, and we report 483 temporally validated results. All pregnancies were managed according to local guidelines, although these were broadly consistent, in line with national and international guidelines (4, 16, 60, 61) and 484 485 current RCT evidence (e.g. the TRUFFLE trial). This introduces variation, but potentially better 486 reflects real-world practice and hence adds external validity. All serum analysis was carried out after 487 pregnancy outcomes were obtained, using a proteomic discovery science approach which did not 488 assume associations with outcome, but also included additional analysis of proteins anticipated to 489 be related to pregnancy outcome in placental insufficiency. Placental histological classification was 490 blinded to pregnancy outcomes and included control and non-FGR preterm placental samples, to 491 remove some potential bias. Finally, our inclusion of stakeholders to guide model selection means 492 that their predictive value is most important to patients and clinicians.

Page 27

#### **IMPPICT JCI version 1**

493	Our relatively narrow inclusion criteria are both a strength and a limitation, in that they have
494	allowed us to focus on a specific clinical group but have limited our sample size and the
495	generalisability of our findings. The sample size means our study was underpowered to demonstrate
496	small or medium effects and our estimates have wider confidence intervals than larger studies (62).
497	The exclusion of pregnancies <3 <sup>rd</sup> centile but >600g limits the number of pregnancies from 24+6
498	weeks of gestation to which our findings can be applied and the exclusion of pregnancies with
499	known genetic, chromosomal, and structural differences means our findings cannot be applied to
500	the whole spectrum of FGR. Generalisability is also limited to healthcare settings with comparable
501	neonatal care provision and outcomes, given their impact on neonatal survival and decision making
502	for iatrogenic preterm delivery. Clinicians managing the pregnancies were not blinded to ultrasound
503	measurements, and indeed many management decisions will have been influenced by ultrasound
504	findings. This could have biased the apparent associations between ultrasound variables and
505	pregnancy outcomes, either artificially strengthening or weakening them.
506	

#### 507 **Future directions**

Ideally, our findings should be independently and externally validated. Given the incidence of FGR 508 ≤28+0 weeks this would require another multicentre study. Further research is also needed to 509 510 determine whether the use of these models would have benefit in practice, both on the 511 psychological wellbeing of parents and on the use of health resources. Future studies to identify and validate predictive models in early-onset SGA (EFW <10<sup>th</sup> centile <32+0 weeks of gestation) would 512 allow application to a wider population. This would complement the work currently being done in 513 514 the PLANES study, which is investigating the impact of revealed PIGF in SGA from 32+0 weeks (63). Finally, our primary outcome of fetal or neonatal death provides only short-term information, and 515 data collection for 2-year neurodevelopmental outcomes is on-going. 516

517

Page 28

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

#### 518 Conclusion

- 519 In conclusion, our study provides validated models for predicting fetal or neonatal death and fetal
- 520 death or delivery ≤28+0 weeks of gestation based on ultrasound and maternal serum protein
- 521 measurements at the time of diagnosis of severe early-onset FGR. The EFW z-score and umbilical
- 522 artery Doppler velocimetry were the best performing ultrasound parameters, but are vulnerable to
- 523 inter-rater variability, variation in formulae and reference ranges and temporal variation. The
- 524 biomarker PIGF was the best performing maternal serum protein for predicting both pregnancy
- 525 outcomes and maternal vascular malperfusion. This identification of a specific pathological
- 526 phenotype may be useful for targeting future potential therapies.
- 527
- 528
- 529
- 530
- 531
- 532
- 533
- 534

535

536

## 537 Methods

538 This study is reported according to the 'strengthening the reporting of observational studies in

- 539 epidemiology' (STROBE) guidelines (64) for cohort studies and the 'transparent reporting of a
- 540 multivariable prediction model for individual prognosis or diagnosis' (TRIPOD) guidelines (65).

541 **Study design and setting:** The EVERREST Prospective Study was a multicentre prospective cohort

542 study recruiting pregnant women from four European tertiary referral centres: University College Page 29

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

543 London Hospital, UK; University Medical Centre Hamburg-Eppendorf, Germany; Maternal-Fetal Unit

544 Hospital Clinic Barcelona, Spain; Skane University Hospital, Lund, Sweden.

545 **Study population:** Full details of the protocol have been published previously (26). In brief, pregnant

- 546 women were eligible if they had a singleton fetus with an ultrasound estimated fetal weight (EFW)
- 547 <600g and <3<sup>rd</sup> centile according to local criteria between 20+0 and 26+6 weeks of gestation.

548 Exclusion criteria were a known abnormal karyotype or major fetal structural abnormality at

549 enrolment (66), indication for immediate delivery, preterm rupture of membranes before

enrolment, maternal HIV or hepatitis B or C infection, maternal age under 18 years, any medical or

551 psychiatric condition which compromised a woman's ability to participate and lack of capacity to

552 consent. Pregnancies with a known congenital infection were not recruited and for the purposes of

this analysis pregnancies ending in termination were excluded.

554 **Outcomes:** The primary outcome was fetal or neonatal death (≤28 days of life). Secondary outcomes

555 were: fetal death or delivery ≤28+0 weeks of gestation; slow fetal growth, defined as a worsening of

556 weight deviation of ≥10 percentage points over a two-week interval (including before and after

enrolment) or equivalent trajectory over a longer period (28); and the development of abnormal

558 UmA Dopplers, defined as development of UmA PI >95<sup>th</sup> centile in pregnancies where UmA PI was

559 ≤95<sup>th</sup> centile at enrolment (27). Ascertainment for outcomes of this study was possible, at the latest,

by 29 days of life. Follow-up for neonatal morbidity and infant health and neurodevelopment to the

561 age of 2 years continues.

All pregnancies were managed according to the local fetal medicine unit protocols. Pre-eclampsia was defined according to International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria (67), meaning that, given the presence of FGR, any woman developing new onset hypertension after 20+0 weeks of gestation was classified as having pre-eclampsia rather than pregnancy-induced hypertension. Formalin-fixed placental samples were classified according to

567 Amsterdam consensus criteria by a single assessor (NS) (68). To minimise bias, study placental

Page 30

**IMPPICT JCI version 1** 

samples were mixed with placental samples from healthy term pregnancies and pregnancies
delivering spontaneously preterm, with NS blinded to pregnancy phenotype and outcome during the
assessment.

571 Ultrasound measurements: All ultrasound examinations were performed by staff trained and

validated to the common EVERREST prospective study protocol (26). At each ultrasound scan

573 Doppler velocimetry of the umbilical artery (UmA), uterine artery (UtA), middle cerebral artery

574 (MCA), ductus venosus (DV) and umbilical vein was performed (69). Local EFW formulae and centile

575 charts were used to determine study eligibility, but for consistency all EFWs were recalculated using

the Hadlock 3 formula (incorporating head circumference, abdominal circumference and femur

577 length), with z-scores recalculated using the Marsal chart for descriptive data (supplementary data

578 Equations 1-3) (29, 30). EFWs and z-scores were also recalculated using Intergrowth formulae for

analysis (supplementary data Equations 4 & 5) (31). The effect of alternative Doppler reference

580 charts was explored, with similar results to those presented (70-74).

581 Blinding: Maternal serum protein concentrations were not available to clinicians, participants or

researchers during the pregnancy, as all samples were analysed after complete primary outcome

583 data had been ascertained. Serum PIGF and sflt-1 concentrations were not used as part of clinical

584 care in any of the study centres during the period of recruitment.

585 Sample collection: Maternal blood was collected at study enrolment in BD Vacutainer<sup>®</sup> serum

separating tubes and processed according to the manufacturer's instructions. 500µl serum aliquots

587 were frozen and stored at -80°C. Placental samples, for Amsterdam criteria categorisation, were

588 collected from two areas of each placenta, midway between the cord insertion and margin in areas

589 free from macroscopic infarcts or lesions. Samples were rinsed in PBS, formalin-fixed, wax-

590 embedded, sectioned and stained with H&E.

591 Measurement of a priori candidate biomarkers in maternal serum: PIGF and sflt-1 concentrations

592 were measured using Elecsys<sup>®</sup> electrochemiluminescence immunoassays on a Cobas<sup>®</sup> e411 analyser

Page 31

**IMPPICT JCI version 1** 

593 (Roche Diagnostics). The normalised protein expression (NPX) of 90 additional proteins associated 594 with cardiovascular disease was measured using the Olink® Cardiovascular II proximity extension assay (full list of proteins in supplementary data Table 17). In the discovery set but not the validation 595 596 set VEGFA, VEGFD, VEGFR2, neuropilin 1 and endoglin were measured in triplicate using Quantikine® 597 colorimetric sandwich ELISAs (R&D Systems). 598 Identification of novel candidate biomarkers in maternal serum using liquid chromatography and tandem mass spectrometry: Five pooled serum samples were created on the following basis: (1) 599 600 pregnancies ending in fetal or neonatal death (2) pregnancies ending in neonatal survival with 601 delivery <37+0 weeks of gestation (3) pregnancies ending in neonatal survival with delivery 37+0 602 weeks of gestation or more (4) slow fetal growth trajectory (5) normal fetal growth trajectory. Pooled serum samples were depleted of 12 high-abundance proteins using Proteome Purify<sup>™</sup> 12 603 604 resin, as per the manufacturer's instructions (R&D Systems), concentrated using Vivaspin<sup>©</sup> 500 5kDa 605 Molecular Weight Cut-Off columns (GE Healthcare), reduced with 10mM tris(2carboxyethyl)phosphine hydrochloride then alkylated with 7.5mM iodoacetamide. Pooled samples 606 607 were digested using a trypsin/Lys-C mix, labelled with Tandem Mass Tags<sup>™</sup> (Thermo Fisher 608 Scientific) and combined(75). The combined sample underwent two-dimensional high-performance 609 reverse-phase liquid chromatography and tandem mass spectrometry. In the first dimension, 610 samples were fractionated into 30 at high pH using a Poroshell 300 Extend C18 column (Agilent), 611 following which fractions 1-4 were combined with fractions 27-30 respectively due to low 612 abundance in the first four fractions. The second fractionation was performed on the Ultimate 3000 613 nano-liquid chromatography system using Acclaim<sup>™</sup> PepMap<sup>™</sup> 100 C18 pre-columns and Acclaim<sup>™</sup> PepMap<sup>™</sup> 100 C18 Nano-LC columns run in tandem with analysis on the LTQ (linear trap 614 quadrupole) Orbitrap XL<sup>™</sup> 2.5.5 (all Thermo Fisher Scientific). A blank calibration sample was run 615 616 after every three fractions, and a standard sample of known mass run after every six fractions, for 617 quality control.

Page 32

#### All rights reserved. No reuse allowed without permission.

#### IMPPICT\_JCI\_version\_1

618 Proteins were identified using Proteome Discover V1.4 software (ThermoFisher Scientific) to search 619 the human Swiss-Prot database with the Mascot search engine (Matrix Science Ltd.). Proteins were scored on variability, peptide count, ubiquity, ratio between pools and consistent trend across pools 620 621 (supplementary data Tables 18 & 19). Expression pattern clusters, based on standardised and raw 622 quantification ratios, were generated using the Graphical Proteomics Data Explorer (GPRoX) 623 platform. Based on their scores and expression clusters, five candidate proteins were selected and 624 measured in individual samples using ELISAs. Fibronectin, PSG1 (both R&D Systems) and HPL (DRG 625 International) were measured in the discovery and validation sets while SAA (R&D Systems) and 626 LNPEP (Cloud-clone) were measured in the discovery set only. 627 Priority survey and model selection: An online survey was sent to patients and clinicians asking their 628 opinion on the importance of different pregnancy outcomes and, for each outcome, whether they 629 would prioritise sensitivity or specificity. Models were selected on the basis of the survey results and 630 the model performance metrics described below. Protein models were published online prior to the 631 validation data analysis. Sample size: Since this work involved discovery of novel biomarkers, a formal a priori sample size 632 calculation was not possible. Before analysing the discovery set it was determined that this sample 633 of n=63 with 21 fetal or neonatal deaths gave an 80% power to detect a standardised effect size of 634 635 0.9 (large) to a significance level of 0.05 (76). 636 Statistics: Data analysis was performed using STATA/MP 16.1 software (StataCorp LLC, College 637 Station, USA) unless otherwise specified. Descriptive and investigative variables were tested for 638 skew and kurtosis (77, 78) and handled as symmetrical if there was no evidence of either. PIGF, sflt1, 639 endoglin, VEGFD, NP1, HPL, SAA and LNPEP were transformed to their natural logs and multiplex 640 data was analysed as provided, on a log2 scale. Characteristics of the discovery and validation sets

- 641 were compared using chi-square tests (categorical data), Fisher's exact tests (binary data with sparse

Page 33

## IMPPICT\_JCI\_version\_1

outcomes), 2-sided t tests (symmetrical continuous data) and Mann-Whitney U tests (skewed

643 continuous data).

644	Missing data for BMI (n=5) were imputed using chain equations. Umbilical artery (UmA) PI at
645	enrolment was systematically missing (n=16), with most missing cases having absent or reversed
646	end-diastolic flow (EDF, n=15). Umbilical artery Doppler velocimetry was therefore handled as an
647	interval variable, 'UmA PI category', , where 0=UmA PI ≤95 <sup>th</sup> centile, 1=UmA >95 <sup>th</sup> centile with
648	positive EDF, 2=absent EDF, 3=reversed EDF. Where uterine artery (UtA) PI at enrolment was missing
649	(n=10) a mean UtA PI below or above the 95 <sup>th</sup> centile could be inferred in nine cases where the
650	mean UtA PI was consistently normal (n=1) or abnormal (n=8) respectively at scans prior to and after
651	enrolment and UtA PI values were imputed using multiple imputation. Associations between
652	ultrasound measurements and both fetal or neonatal death and death or delivery $\leq$ 28+0 weeks of
653	gestation, were analysed using logistic regression. Univariate associations between protein
654	concentrations or NPX and outcomes were assessed using 2-sided t tests, Mann-Whitney U tests and
655	logistic regression, with Benjamini-Hochberg procedures to account for multiple comparisons.
656	Model development: Two-protein models for the development of abnormal UmA Dopplers and
657	two- and three-protein models for the other three pregnancy outcomes, with internal validation
658	using leave-one-out cross-validation (LOOCV), were compared based on AUC, specificity for 90%
659	sensitivity, sensitivity for 90% specificity. F1 score, Matthews correlation coefficient (MCC) and
cc0	
660	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package
661	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals
661 662	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the
661 662 663	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the MLmetrics R package (version 1.1.1, <u>https://cran.r-project.org/web/packages/MLmetrics/index.html</u> ).
661 662 663 664	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the MLmetrics R package (version 1.1.1, <u>https://cran.r-project.org/web/packages/MLmetrics/index.html</u> ). Models with variance inflation factors of five or more were excluded using the following R package:
661 662 663 664 665	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the MLmetrics R package (version 1.1.1, <u>https://cran.r-project.org/web/packages/MLmetrics/index.html</u> ). Models with variance inflation factors of five or more were excluded using the following R package: <u>https://cran.r-project.org/web/packages/car/index.html</u> , version 3.1-0. Two-variable models
661 662 663 664 665 666	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the MLmetrics R package (version 1.1.1, <u>https://cran.r-project.org/web/packages/MLmetrics/index.html</u> ). Models with variance inflation factors of five or more were excluded using the following R package: <u>https://cran.r-project.org/web/packages/car/index.html</u> , version 3.1-0. Two-variable models predicting fetal or neonatal death and death or delivery ≤28+0 weeks of gestation containing
661 662 663 664 665 666 667	precision-recall characteristics (PRROC) AUC. ROC curves were generated with the <i>pROC</i> R package (version 1.18.0, <u>https://cran.r-project.org/web/packages/pROC/index.html</u> ). 95% confidence intervals for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the MLmetrics R package (version 1.1.1, <u>https://cran.r-project.org/web/packages/MLmetrics/index.html</u> ). Models with variance inflation factors of five or more were excluded using the following R package: <u>https://cran.r-project.org/web/packages/car/index.html</u> , version 3.1-0. Two-variable models predicting fetal or neonatal death and death or delivery ≤28+0 weeks of gestation containing ultrasound parameters with or without PIGF or HPL (as the proteins showing the strongest

IMPPICT\_JCI\_version\_1

668	associations with these outcomes) were compared in the same way. Outcomes and protein models
669	to be validated were published on the study registry prior to analysis of the validation data.
670	Parenclitic network analysis: Parenclitic networks of the 102 proteins were generated for each of
671	the four pregnancy outcomes. For each outcome, two-dimensional kernel density estimations were
672	generated for every pair-combination of variables in 'controls' (pregnancies without the outcome).
673	Individual networks were then generated for each 'case', with linkages created if a pair-wise
674	relationship of variables differed from the control distribution by more than a given threshold(79).
675	These individual case networks were then combined. VEGF-A, BNP, PARP1 and melusin were
676	included as binary variables of 'detectable' or 'not detectable'. Booking body mass index (BMI) and
677	fetal sex were included as variables in the networks, except for 'development of abnormal UmA
678	Dopplers', where the sample was not large enough to accommodate them.
679	Model validation: Concentrations of HPL and PSG1, as measured by ELISA, and NPX values for the
680	Olink multiplex proteins showed substantial variation in centrality and spread between the discovery
681	and validation sets. To account for this, values of each protein were centred to a mean of 0 and
682	scaled to an SD of 1 in the discovery set and validation set separately. These centred and scaled
683	values were used for subsequent analyses, including model validation. Concentrations of PIGF, sflt1
684	and fibronectin did not require transformation.
685	Models generated from the discovery set were run on data from the validation set and were
686	considered validated if the 95% CI for the validation estimate of AUC included the LOOCV AUC
687	estimate from the discovery set. For validated models, data from both sets were combined to give
688	final test characteristics. Likelihood ratio tests were used to determine whether the addition of
689	pregnancy characteristics (maternal BMI, maternal age, maternal ethnicity, fetal sex, gestational age
690	at enrolment and pre-eclampsia at enrolment) significantly improved the validated models. Model
691	calibration was assessed by plotting predicted probability against observed frequency of outcome.

Page 35

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

Functional interactions: Centred and scaled data from the discovery and validation sets were combined to retest univariate associations with the primary and secondary outcomes. Proteins showing a significant association at a 5% Benjamini-Hochberg false discovery rate were explored for physical and functional interactions and for enrichment of GO biological processes, relative to the background of all proteins measured, using STRING (Swiss Institute of Bioinformatics)(32). Where no enrichment was detected shared GO biological processes were identified through comparison to the whole genome.

699 Modelling pregnancy duration: Protein and ultrasound measurements from the combined discovery 700 and validation sets were tested for their association with gestational age at livebirth or diagnosis of 701 fetal death and interval from enrolment to livebirth or diagnosis of fetal death using linear 702 regression. Variables showing a significant association at a 1% Benjamini-Hochberg false discovery 703 rate were used to create linear models predicting these outcomes in a stepwise fashion. Maternal 704 age, BMI, ethnicity, gestational age at enrolment, pre-eclampsia at enrolment and fetal sex were 705 tested for model improvement. Model fit was tested by assessing variance inflation factors for 706 multicollinearity, assessing the distribution of the residuals for heteroscedasticity and outliers, and 707 looking for observations with high leverage. UmA and UtA Doppler velocimetry, PIGF concentration, 708 HPL concentration and PAPP-A NPX were tested for their associations with placental histological 709 classification using logistic regression. 710 Study approval: Ethical approval was provided by the National Research Ethics Service Committee

London - Stanmore in the UK (REC reference: 13/LO/1254), the Hospital Clinic of Barcelona's Clinical
Research Ethics Committee in Spain (Reg: HCB/2014/0091), the Regional Ethical Review Board in
Lund for Sweden, (DNr 2014/147) and the Ethics Committee of Hamburg Board of Physicians in
Germany (PV4809). This study was conducted according to the Declaration of Helsinki principles and
written informed consent was given by all participants before enrolment.

716

Page 36

**IMPPICT JCI version 1** 

# 717 Acknowledgements

718	The research leading to these results has received funding from the European Union Seventh
719	Framework Programme (FP7/2007-2013) under grant agreement no. 305823, the Rosetrees Trust
720	and the Mitchell Charitable Trust in memory of Shoshana Mitchell Glynn. This research has been
721	supported by the National Institute for Health Research University College London Hospitals
722	Biomedical Research Centre (RS, NM, ALD). NRN would like to thank the support from Cancer
723	Research UK (C12077/A26223).
724	
725	This work would not have been possible without the contribution of the late Professor John Timms,
726	Elizabeth Garrett Anderson Institute for Women's Health, University College London. His
727	contribution to the design, conduct and analysis of the study was invaluable, and we would have
728	been honoured to have him as a co-author. We would also like to thank all of the women and
729	families who took part in this study as well as staff at the UCL Comprehensive Clinical Trials Unit
730	(Anna Morka, Jade Dyer, Helen Knowles, Steve Hibbert, Kate Maclagan), Gina Buquis, Jade Okell, Dr
731	Mark Lees, Dr Carlo Rossi, Dr Tara Krishnan, Dr Roberta Morris, Dr Sarah Guillon, Richard Gunu, Dr
732	Eva Sedlak, Professor Alexei Zaikin and Dr Oleg Blyuss.

733 Data access statement: The full data set will not be made publicly available because the degree of

- detailed phenotyping could allow individual patient identification. Limited data sharing may be
- possible, with the agreement of the consortium, on request to RS or ALD.

# 736 **References**

- Zur RL, Kingdom JC, Parks WT, Hobson SR. The Placental Basis of Fetal Growth Restriction.
   Obstetrics and gynecology clinics of North America. 2020;47(1):81-98.
- Sun C, Groom KM, Oyston C, Chamley LW, Clark AR, James JL. The placenta in fetal growth
   restriction: What is going wrong? Placenta. 2020;96:10-8.
- 3. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al.
- 742 Consensus definition for placental fetal growth restriction: a Delphi procedure. Ultrasound Obstet
- 743 Gynecol. 2016;48(3):333-9.

Page 37

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

744 4. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG Practice 745 Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth 746 restriction. Ultrasound Obstet Gynecol. 2020;56(2):298-312. 747 5. Society for Maternal-Fetal Medicine, Martins JG, Biggio JR, Abuhamad A. Society for 748 Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction. 749 Am J Obstet Gynecol. 2020;223(4):B2-B17. 750 6. Ganzevoort W, Thornton JG, Marlow N, Thilaganathan B, Arabin B, Prefumo F, et al. 751 Comparative analysis of 2-year outcomes in GRIT and TRUFFLE trials. Ultrasound Obstet Gynecol. 2020;55(1):68-74. 752 753 7. Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Maternal sildenafil for 754 severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-755 blind trial. Lancet Child Adolesc Health. 2018;2(2):93-102. 756 Villar J, Restrepo-Méndez MC, McGready R, Barros FC, Victora CG, Munim S, et al. 8. 757 Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and 758 Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study. JAMA Pediatr. 759 2021;175(5):483-93. 760 Pels A, Beune IM, van Wassenaer-Leemhuis AG, Limpens J, Ganzevoort W. Early-onset fetal 9. 761 growth restriction: A systematic review on mortality and morbidity. Acta Obstet Gynecol Scand. 2020;99(2):153-66. 762 763 Rock CR, White TA, Piscopo BR, Sutherland AE, Miller SL, Camm EJ, et al. Cardiovascular and 10. 764 Cerebrovascular Implications of Growth Restriction: Mechanisms and Potential Treatments. 765 International journal of molecular sciences. 2021;22(14). 766 11. Arigliani M, Stocco C, Valentini E, De Pieri C, Castriotta L, Ferrari ME, et al. Lung function 767 between 8 and 15 years of age in very preterm infants with fetal growth restriction. Pediatr Res. 768 2021;90(3):657-63. 769 Mappa I, Magina P, Bitsadze V, Khizroeva J, Makatsarya A, Arduini D, et al. Cardiac function 12. 770 in fetal growth restriction. Minerva Obstet Gynecol. 2021;73(4):423-34. 771 13. Fernandez-Twinn DS, Hjort L, Novakovic B, Ozanne SE, Saffery R. Intrauterine programming 772 of obesity and type 2 diabetes. Diabetologia. 2019;62(10):1789-801. 773 14. Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al. FIGO 774 (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice 775 advice for screening, diagnosis, and management of fetal growth restriction. Int JGynaecol Obstet. 776 2021;152 Suppl 1:3-57. 777 Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention 15. 778 and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S829-S40. 779 Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 31: The 16. 780 Investigation and Management of the Small-for-Gestation-Age Fetus. London: RCOG; 2014. 781 Ormesher L, Warrander L, Liu Y, Thomas S, Simcox L, Smith GCS, et al. Risk stratification for 17. 782 early-onset fetal growth restriction in women with abnormal serum biomarkers: a retrospective 783 cohort study. Scientific reports. 2020;10(1):22259. 784 18. Sovio U, Goulding N, McBride N, Cook E, Gaccioli F, Charnock-Jones DS, et al. A maternal 785 serum metabolite ratio predicts fetal growth restriction at term. Nat Med. 2020;26(3):348-53. Tong S, Joy Kaitu'u-Lino T, Walker SP, MacDonald TM. Blood-based biomarkers in the 786 19. 787 maternal circulation associated with fetal growth restriction. Prenat Diagn. 2019;39(11):947-57.

Romero Infante XC, Uriel M, Porras Ramírez A, Rincón Franco S. Comparison of preeclampsia
 and fetal growth restriction screenings at first trimester in a high-risk population. J Obstet Gynaecol
 Res. 2021;47(2):765-73.

791 21. Asvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A. Angiogenic

factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol.
 2011;173(6):630-9.

Page 38

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of
uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction:
a systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701-11.
Harvey ME, David AL, Dyer J, Spencer R. Pregnant women's experiences and perceptions of

participating in the EVERREST prospective study; a qualitative study. BMC Pregnancy Childbirth.2019;19(1):144.

800 24. Blakeley C, Smith DM, Johnstone ED, Wittkowski A. Women's lived experiences of a prenatal
801 diagnosis of fetal growth restriction at the limits of viability: An interpretative phenomenological
802 study. Midwifery. 2019;76:110-7.

25. David AL. Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth
 restriction. Placenta. 2017;59 Suppl 1:S44-S50.

Spencer R, Ambler G, Brodszki J, Diemert A, Figueras F, Gratacos E, et al. EVERREST
prospective study: a 6-year prospective study to define the clinical and biological characteristics of
pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth.
2017;17(1):43.

809 27. Schaffer AC, Staudach A. Doppler-Referenzkurven. 1997.

810 28. Marsal K. Obstetric management of intrauterine growth restriction. Best Pract Res Clin
811 Obstet Gynaecol. 2009;23:857-70.

Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the
use of head, body, and femur measurements--a prospective study. Am J Obstet Gynecol.
1985;151(3):333-7.

81530.Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based816on ultrasonically estimated foetal weights. Acta Paediatr. 1996;85(7):843-8.

Stirnemann J, Villar J, Salomon LJ, Ohuma E, Ruyan P, Altman DG, et al. International
estimated fetal weight standards of the INTERGROWTH-21st Project. Ultrasound Obstet Gynecol.
2017;49(4):478-86.

32. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in
2021: customizable protein-protein networks, and functional characterization of user-uploaded
gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605-D12.

33. Mahajan D, Sharma NR, Kancharla S, Kolli P, Tripathy A, Sharma AK, et al. Role of Natural
Killer Cells during Pregnancy and Related Complications. Biomolecules. 2022;12(1).

34. Thomas JR, Appios A, Zhao X, Dutkiewicz R, Donde M, Lee CYC, et al. Phenotypic and
functional characterization of first-trimester human placental macrophages, Hofbauer cells. J Exp
Med. 2021;218(1).

828 35. Raguema N, Moustadraf S, Bertagnolli M. Immune and Apoptosis Mechanisms Regulating
829 Placental Development and Vascularization in Preeclampsia. Front Physiol. 2020;11:98.

830 36. Schrimpf C, Teebken OE, Wilhelmi M, Duffield JS. The role of pericyte detachment in vascular
831 rarefaction. J Vasc Res. 2014;51(4):247-58.

37. Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk
pregnancies. Cochrane Database Syst Rev. 2010(1):CD007529.

834 38. Morris RK, Malin G, Robson SC, Kleijnen J, Zamora J, Khan KS. Fetal umbilical artery Doppler
835 to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and
836 bivariate meta-analysis. Ultrasound Obstet Gynecol. 2011;37(2):135-42.

837 39. Baião AER, de Carvalho PRN, Moreira MEL, de Sá RAM, Junior SCG. Predictors of perinatal
838 outcome in early-onset fetal growth restriction: A study from an emerging economy country. Prenat
839 Diagn. 2020;40(3):373-9.

40. Sharp A, Jackson R, Cornforth C, Harrold J, Turner MA, Kenny L, et al. A prediction model for

short-term neonatal outcomes in severe early-onset fetal growth restriction. Eur J Obstet GynecolReprod Biol. 2019;241:109-18.

Page 39

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

843 41. Baschat AA, Gembruch U, Reiss I, Gortner L, Weiner CP, Harman CR. Relationship between
844 arterial and venous Doppler and perinatal outcome in fetal growth restriction. Ultrasound Obstet
845 Gynecol. 2000;16(5):407-13.

846 42. Bilardo CM, Wolf H, Stigter RH, Ville Y, Baez E, Visser GH, et al. Relationship between
847 monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction.
848 Ultrasound Obstet Gynecol. 2004;23(2):119-25.

43. The investigation and management of the small-for gestational age fetus. Green-topGuideline No 31. London: Royal College of Obstetricians and Gynaecologists; 2013.

44. Thomas RL, Peng TC, Eglinton GS, Strobino DM, Johnson TR. Precision of umbilical artery
Doppler studies. Intraobserver, interobserver, and biologic variability of fetal Doppler velocimetry. J
Ultrasound Med. 1991;10(4):201-4.

854 45. Bruin CM, Ganzevoort W, Schuit E, Mensing van Charante NA, Wolf H. Inter- and intra855 observer variability in fetal ductus venosus blood flow measurements in high-risk fetuses at 26-32
856 weeks. Eur J Obstet Gynecol Reprod Biol. 2019;243:67-71.

46. Pasquini L, Marchi L, Gaini C, Franchi C, Mecacci F, Bilardo CM. Intra- and Interobserver
Reproducibility of Third Trimester Middle Cerebral Artery Pulsatility Index Measurement: A
Prospective Cross-Sectional Study. Fetal Diagn Ther. 2020;47(3):214-9.

Steller JG, Driver C, Gumina D, Peek E, Harper T, Hobbins JC, et al. Doppler velocimetry
discordance between paired umbilical artery vessels and clinical implications in fetal growth
restriction. Am J Obstet Gynecol. 2022;227(2):285 e1- e7.

48. Oros D, Ruiz-Martinez S, Staines-Urias E, Conde-Agudelo A, Villar J, Fabre E, et al. Reference
ranges for Doppler indices of umbilical and fetal middle cerebral arteries and cerebroplacental ratio:
systematic review. Ultrasound Obstet Gynecol. 2019;53(4):454-64.

866 49. Sarris I, Ioannou C, Chamberlain P, Ohuma E, Roseman F, Hoch L, et al. Intra- and
867 interobserver variability in fetal ultrasound measurements. Ultrasound Obstet Gynecol.
868 2012;39(3):266-73.

Anderson NG, Jolley IJ, Wells JE. Sonographic estimation of fetal weight: comparison of bias,
 precision and consistency using 12 different formulae. Ultrasound Obstet Gynecol. 2007;30(2):173-9.

S1. Choi SKY, Gordon A, Hilder L, Henry A, Hyett JA, Brew BK, et al. Performance of six birthweight and estimated-fetal-weight standards for predicting adverse perinatal outcome: a 10-year
nationwide population-based study. Ultrasound Obstet Gynecol. 2021;58(2):264-77.

52. Warrander LK, Ingram E, Heazell AEP, Johnstone ED. Evaluating the accuracy and precision of
sonographic fetal weight estimation models in extremely early-onset fetal growth restriction. Acta
Obstet Gynecol Scand. 2020;99(3):364-73.

877 53. Mendoza M, Hurtado I, Bonacina E, Garcia-Manau P, Serrano B, Tur H, et al. Individual risk
878 assessment for prenatal counseling in early-onset growth-restricted and small-for-gestational-age
879 fetuses. Acta Obstet Gynecol Scand. 2021;100(3):504-12.

S4. Quezada MS, Rodríguez-Calvo J, Villalaín C, Gómez-Arriaga PI, Galindo A, Herraiz I. sFlt1/PIGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical
artery flow. Ultrasound Obstet Gynecol. 2020;56(4):549-56.

55. Shinar S, Tigert M, Agrawal S, Parks WA, Kingdom JC. Placental growth factor as a diagnostic tool for placental mediated fetal growth restriction. Pregnancy hypertension. 2021;25:123-8.

885 56. Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, et al. Placental
886 growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta.
887 2016;42:1-8.

888 57. Agrawal S, Parks WT, Zeng HD, Ravichandran A, Ashwal E, Windrim RC, et al. Diagnostic

889 utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in

diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction. Am JObstet Gynecol. 2022.

Page 40

All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

58. Triunfo S, Lobmaier S, Parra-Saavedra M, Crovetto F, Peguero A, Nadal A, et al. Angiogenic
factors at diagnosis of late-onset small-for-gestational age and histological placental underperfusion.
Placenta. 2014;35(6):398-403.

Schiffer V, Borghans CWJ, Arts N, Bons JAP, Severens-Rijvers CAH, van Kuijk SMJ, et al. The
association between first trimester placental biomarkers and placental lesions of maternal vascular
malperfusion. Placenta. 2021;103:206-13.

Lausman A, Kingdom J, Gagnon R, Basso M, Bos H, Crane J, et al. Intrauterine growth
restriction: screening, diagnosis, and management. J Obstet Gynaecol Can. 2013;35(8):741-57.
Perinatal Society of Australia and New Zealand and Centre of Research Excellence Stillbirth.

901 Position statement: detection and management of fetal growth restriction in singleton pregnancies.
902 Brisbane, Australia: Centre of Research Excellence in Stillbirth.; 2019.

90362.Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive Value of904the sFlt-1:PIGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13-22.

Gent J, Bullough S, Harrold J, Jackson R, Woolfall K, Andronis L, et al. The PLANES study: a
protocol for a randomised controlled feasibility study of the placental growth factor (PIGF) blood
test-informed care versus standard care alone for women with a small for gestational age fetus at or
after 32 + 0 weeks' gestation. Pilot Feasibility Stud. 2020;6(1):179.

909 64. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al.
910 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and
911 elaboration. PLoS medicine. 2007;4(10):e297.

65. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BJOG.

914 2015;122(3):434-43.

915 66. Carvalho MHB, Brizot ML, Lopes LM, Chiba CH, Miyadahira S, Zugaib M. Detection of fetal 916 structural abnormalities at the 11–14 week ultrasound scan. Prenat Diagn. 2002;22(1):1-4.

917 67. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The

918 hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management

919 recommendations for international practice. Pregnancy hypertension. 2018;13:291-310.

920 68. Khong TY, Mooney EE, Ariel I, Balmus NC, Boyd TK, Brundler MA, et al. Sampling and

Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch
 Pathol Lab Med. 2016;140(7):698-713.

923 69. Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafici D, Hernandez-Andrade E, et al. ISUOG
924 practice guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol.
925 2013;41:233-9.

926 70. Arduini D, Rizzo G. Normal values of Pulsatility Index from fetal vessels: a cross-sectional
927 study on 1556 healthy fetuses. J Perinat Med. 1990;18(3):165-72.

928 71. Gómez O, Figueras F, Fernández S, Bennasar M, Martínez JM, Puerto B, et al. Reference
929 ranges for uterine artery mean pulsatility index at 11–41 weeks of gestation. Ultrasound Obstet
930 Gynecol. 2008;32(2):128-32.

931 72. Hofstaetter C, Dubiel M, Gudmundsson S, Marsal K. Uterine artery color Doppler assisted
932 velocimetry and perinatal outcome. Acta Obstet Gynecol Scand. 1996;75(7):612-9.

933 73. Gudmundsson S, Marsal K. Umbilical artery and uteroplacental blood flow velocity

waveforms in normal pregnancy--a cross-sectional study. Acta Obstet Gynecol Scand.
1988;67(4):347-54.

936 74. Mari G, Deter RL. Middle cerebral artery flow velocity waveforms in normal and small-for-937 gestational-age fetuses. Am J Obstet Gynecol. 1992;166(4):1262-70.

938 75. Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, et al. Improved 939 early detection of ovarian cancer using longitudinal multimarker models. Br J Cancer

939 early detection of ovarian cancer using longitudinal multimarker models. Br J Cancer.

940 2020;122(6):847-56.

Page 41

perpetuity. All rights reserved. No reuse allowed without permission.

IMPPICT\_JCI\_version\_1

- 76. Cohen J. Statistical Power Analysis for Behavioural Sciences (2nd edition): Lawrence Erlbaum942 Associates; 1988.
- 943 77. D'Agostino R, Belanger J, D'Agostino RJ. A suggestion for using powerful and informative
  944 tests of normality. American Statistician. 1990;44:316-21.
- 78. Royston P. Comment on sg3.4 and an improved D'Agostino test. Stata Technical Bulletin.1991;2:16-7.
- 947 79. Whitwell HJ, Blyuss O, Menon U, Timms JF, Zaikin A. Parenclitic networks for predicting
- 948 ovarian cancer. Oncotarget. 2018;9(32):22717-26.

949

Page 42